Daniel Tranen (Partner-St. Louis, MO) was quoted in “Loper Bright Supreme Court Case Decision Creates Risk for FDA-Regulated Companies,” published in The Hartford Insights on October 14, 2024. The article noted that many believe the decision in the Loper Bright case has the potential to encourage innovation because it could give more leverage to companies choosing to challenge federal agency rules and statute interpretations in court. Dan explains Loper Bright could instead dampen future innovation. “This decision is likely ultimately to be an attack on regulation by federal agencies. However, innovation generally flourishes under stable conditions that make innovation less risky and less costly on average. Loper potentially upends the stability of the past 40 years by pushing the ultimate decision-making on interpretation of federal statutes to courts and away from federal agencies. The interpretive decisions of judges who may lack expertise, and may be more politically driven, may contribute to more chaos in the regulatory environment.”